Recent developments in the AI chip sector include a notable collaboration between VERAXA Biotech and Ardigen. This partnership focuses on integrating artificial intelligence into drug discovery processes to enhance VERAXA's BiTAC pipeline, targeting cancer treatments. The AI will aid in selecting synergistic cancer target pairs, potentially improving therapeutic outcomes by reducing toxicity and systemic effects. This initiative highlights the growing role of AI chips in revolutionizing...